O-151 Phase II study of anatumomab mafenatox (ABR-214936) in advanced NSCLC: Results of a multi-institutinal open label repeat dose trial with patient-specific dose escalation
Langer, Corey J., Katherine Alpaugh, R., Robert, Francisco, Weiner, L.M., Schiller, Joan, Kopreski, M., Rogatko, Andre, Forsberg, GoranVolume:
41
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(03)91809-5
Date:
August, 2003
File:
PDF, 188 KB
english, 2003